Mefloquine neurotoxicity and gap junction blockade: critical insights in drug repositioning.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada.Neurology and therapy · 2016
   Article
2. Behavioral effects of mefloquine in tail suspension and light/dark tests.SpringerPlus · 2015
   Article
3. Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine.International journal for parasitology. Drugs and drug resistance · 2014
   Article
4. Quantitative mapping of trimethyltin injury in the rat brain using magnetic resonance histology.Neurotoxicology · 2014
   Article
5. Regulation of cellular communication by signaling microdomains in the blood vessel wall.Pharmacological reviews · 2014
   Review

Corrections and comments

• Comment on
  Mefloquine neurotoxicity is mediated by non-receptor tyrosine kinase.2011

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as